Surfactant therapy and intravenous zanamivir in severe respiratory failure due to persistent influenza A/H1N1 2009 virus infection

Am J Respir Crit Care Med. 2010 Nov 15;182(10):1334. doi: 10.1164/ajrccm.182.10.1334.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acute Disease
  • Biological Products / administration & dosage
  • Biological Products / therapeutic use*
  • Bronchoscopy
  • Child
  • Female
  • Humans
  • Influenza A Virus, H1N1 Subtype*
  • Influenza, Human / complications
  • Influenza, Human / drug therapy*
  • Infusions, Intravenous
  • Phospholipids / administration & dosage
  • Phospholipids / therapeutic use*
  • Pulmonary Surfactants / administration & dosage
  • Pulmonary Surfactants / therapeutic use*
  • Respiratory Insufficiency / drug therapy*
  • Respiratory Insufficiency / etiology
  • Zanamivir / administration & dosage
  • Zanamivir / therapeutic use*

Substances

  • Biological Products
  • Phospholipids
  • Pulmonary Surfactants
  • poractant alfa
  • Zanamivir